Does BUTYLSCOPOLAMINE Cause Malignant neoplasm progression? 8 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Malignant neoplasm progression have been filed in association with BUTYLSCOPOLAMINE. This represents 0.9% of all adverse event reports for BUTYLSCOPOLAMINE.
8
Reports of Malignant neoplasm progression with BUTYLSCOPOLAMINE
0.9%
of all BUTYLSCOPOLAMINE reports
5
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From BUTYLSCOPOLAMINE?
Of the 8 reports, 5 (62.5%) resulted in death, 3 (37.5%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BUTYLSCOPOLAMINE. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does BUTYLSCOPOLAMINE Cause?
Drug ineffective (178)
Headache (103)
Off label use (103)
Hypersensitivity (99)
Swelling face (89)
Drug ineffective for unapproved indication (85)
Vomiting (84)
Swollen tongue (82)
Angioedema (81)
Drug abuse (81)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which BUTYLSCOPOLAMINE Alternatives Have Lower Malignant neoplasm progression Risk?
BUTYLSCOPOLAMINE vs BYDUREON
BUTYLSCOPOLAMINE vs BYETTA
BUTYLSCOPOLAMINE vs BYETTA PEN DISPOSABLE
BUTYLSCOPOLAMINE vs CABAZITAXEL
BUTYLSCOPOLAMINE vs CABERGOLINE